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Female partners of prostate cancer (PCa) survivors experience heightened psychological 
distress that may be greater than that expressed by PCa patients. However, optimal 
approaches to detect distressed, or at risk of distress, partners are unclear. This study applied 
receiver operating characteristics analysis to evaluate diagnostic accuracy, sensitivity and 
specificity of the Distress Thermometer (DT) compared to widely-used measures of general 
(Hospital Anxiety and Depression Scale) and cancer-specific (Impact of Events Scale–
Revised) distress. Participants were partners of men with localised PCa (recruited around 
diagnosis) about to undergo or had received surgical treatment (N=189), and partners of men 
diagnosed with PCa who were 2-4 years post-treatment (N=460).  In both studies, diagnostic 
utility of the DT overall was not optimal. Although area under the curve scores were 
acceptable (ranges: 0.71 to 0.92 and 0.83 to 0.94 for general and cancer-specific distress, 
respectively); sensitivity, specificity and optimal DT cut-offs for partner distress varied for 
general (range: ≥2 to ≥5) and cancer-specific (range: ≥3 to ≥5) distress both across time and 
between cohorts. Thus, it is difficult to draw firm conclusions about the diagnostic 
capabilities of the DT for partners or recommend its use in this population. More 
comprehensive screening measures may be needed to detect partners needing psychological 
intervention. 
 
















Globally, prostate cancer (PCa) is the second most common cancer diagnosed in 
males and the fifth leading cause of cancer death (Torre et al., 2015). Five year prevalence 
estimates suggest that there are over 3.8 million short- to medium-term PCa survivors 
globally, with this number expected to increase rapidly in future (Torre et al., 2015). The 
physical and psychological effects of PCa diagnosis and treatment on these men are well 
described (Chambers et al., 2017; Chambers, Zajdlewicz, Youlden, Holland, & Dunn, 2014; 
Hinz et al., 2009; Potosky et al., 2004; Punnen, Cowan, Chan, Carroll, & Cooperberg, 2015), 
and research is now focusing on the psychological morbidity experienced by their 
female partners (Chambers et al., 2017). Specifically, between 36-49% partners of men 
with prostate cancer report mild to severe anxiety and 9-10% indicate mild to severe 
depression (Cliff & MacDonagh, 2000) (Chambers et al., 2012),  and 20% experience 
heightened cancer-specific distress (Eton, Lepore, & Helgeson, 2005). Evidence also 
shows that some partners experience more distress than patients (Cliff & MacDonagh, 
2000; Couper et al., 2006; Eton et al., 2005) .  Partner distress can be long-term, with 
greater distress linked to disease-related (e.g., increased caregiver burden, disease-specific 
quality of life), individual (e.g., coping style, stress appraisal, physical health), and 
relationship (e.g., decreased relationship satisfaction, intimacy or functioning) factors 
(Chambers et al., 2018; Couper et al., 2006; Harden et al., 2013; Hyde  et al.; Wootten, 
Abbott, Farrell, Austin, & Klein, 2014).  
In order to facilitate and better target psychological interventions and supportive care 
in the oncology setting to those who are most likely to benefit, it is necessary to first identify 
who is distressed and from this refer to an appropriate level of psychosocial care 
(Hutchison et al., 2006). This approach ensures valuable and often scarce resources are 
directed to where they are most needed. Standards for optimal oncology care advise that 




screening for distress and referral to evidence-based services is needed as part of routine care 
(Holland, Watson, & Dunn, 2011). Ultra-short screening measures (< 5 items, < 2 minutes to 
complete) are more easily integrated with the demands of clinical care settings (time- and 
cost-efficient), help to promote universal access to psychological services, and are 
recommended as an initial step to identify patients who may be distressed (Vodermaier, 
Linden, & Siu, 2009). The distress thermometer (DT) is widely used with cancer patients as a 
brief screen to detect overall emotional distress (Lazenby, Tan, Pasacreta, Ercolano, & 
McCorkle, 2015; Vodermaier et al., 2009). Meta-analysis of validation studies and systematic 
reviews support an optimal DT cut-off >4 to indicate at least moderate distress requiring 
more in-depth assessment, intervention or referral (Butow et al., 2015; Ma et al., 2014; 
Mitchell, 2007; Vodermaier et al., 2009). Although use of the DT and its validity is well 
established for cancer patients including men diagnosed with PCa, (Chambers et al., 2014; 
Roth et al., 1998), the optimal approach for detecting heightened distress in thee partners of 
these men is unclear.  
A rapid review conducted for the purposes of this study found that quantitative studies 
with partners or caregivers of adult cancer patients which included the DT as a measure to 
assess distress (predictor or outcome) typically used a DT cut-off ≥4 (Chambers et al., 2014; 
Chambers et al., 2012; Chatterton et al., 2015; Fujinami et al., 2015; Howell et al., 2011; 
Hughes, Sargeant, & Hawkes, 2011; Hutchison et al., 2011; Morris et al., 2015; Trad et al., 
2015) or ≥5 (Badr, Gupta, Sikora, & Posner, 2014; Feiten et al., 2013; Goebel, von Harscher, 
& Mehdorn, 2011; Goldzweig, Rottenberg, Peretz, & Baider, 2015; Halkett et al., 2016; 
Juarez, Ferrell, Uman, Podnos, & Wagman, 2008; Long et al., 2016; Sklenarova, Haun, et al., 
2015; Ugalde, Krishnasamy, & Schofield, 2014; Weide et al., 2012; Zwahlen, Hagenbuch, 
Jenewein, Carley, & Buchi, 2011). However, systematic reviews and meta-analyses of studies 




validating the DT or brief screening measures in the cancer context are silent with regards to 
the optimal DT cut-off to identify distress in partners/caregivers.  
To our knowledge three studies (Bevans et al., 2011; Hawkes, Hughes, Hutchison, & 
Chambers, 2010; Zwahlen, Hagenbuch, Carley, Recklitis, & Buchi, 2008) have validated the 
DT in family members or caregivers using receiver operating characteristics (ROC) analysis. 
Zwahlen et al. (2008) compared the DT to the HADS anxiety and depression subscales and 
recommended it for use in clinical assessment of family members of outpatients with cancer. 
A DT cut-off of 3-4 or 4-5 was proposed as optimal for sensitivity (anxiety and depression 
≥0.86) and a cut-off of 4-5 for acceptable specificity (anxiety 0.71, depression 0.68). By 
comparison, Hawkes et al. (2010) compared the DT to the HADS in carers of cancer patients 
who contacted a cancer helpline and recommended a DT cut-off of ≥6. However, although 
discriminant ability of the DT (AUC 0.70) and sensitivity (0.77) were acceptable, specificity 
was poor (0.48). Bevans et al. (2011) compared the DT to the Brief Symptom Inventory-18 in 
caregivers of patients undergoing allogeneic hematopoietic stem cell transplant. Discriminant 
ability of the DT was poor (AUC 0.61), and no clear consensus was obtained on an 
appropriate DT cut-off.   
Cancer-specific distress is also an important outcome for caregivers of cancer 
patients. For example, in a study of 427 female partners of prostate cancer survivors (2-
4 years post treatment) who were followed up over 24 months, higher caregiver burden 
and more threat appraisals were associated with increased distress, anxiety, depression, 
and cancer-specific distress over time (as measured by the HADS and Impact of Events 
Scale-Revised [IES-R]) (Chambers et al., 2018). However, there does not appear to be 
any published studies examining validity of the DT against cancer-specific distress 
measures such as the IES-R. In sum, there is limited data to guide use of the DT in partners 




or carers of cancer patients and no data at all on how useful this scale might be for the 
partners of men with PCa. 
There is a need for guidance regarding diagnostic utility of the DT and its 
appropriateness for use in oncology and community and primary care settings with partners 
of cancer patients, and in particular partners of men with PCa. Accordingly, we undertook 
ROC analyses in two cohorts of women whose partners had been previously diagnosed with 
PCa. Specifically, we assessed sensitivity and specificity of the DT when compared to 
general (HADS) and cancer-specific (IES-R) distress, and performance of the DT over time 




Participants were 189 partners of men with localised PCa (recruited around diagnosis) 
who had chosen or received surgical treatment (Chambers et al., 2008; Chambers et al., 
2013). In brief, mean age of partners was 59.8 years (SD = 7.4; range 40.0 to 75.0). Most 
(96%) partners were married (length of relationship M = 32.5 years, SD = 11.8, range = 0.5 
to 51.0) and 30% had children living at home. Approximately half (48%) had a university 
degree or technical certificate and 40% had a gross household income below AUD$60,000 
per annum.  
Study 2 
Participants were 460 female partners of men previously diagnosed with PCa (2 to 4 
years post-treatment), identified through an existing study (Chambers et al., 2017). In brief, 
partners were mean age 62.8 years (SD = 8.0; range = 29.5-83.0); 96% were married; mean 
length of relationship was 36.3 years (SD = 12.8; range = 2.1 to 59.5); 21% had children 




living at home. Under half (44%) had a university degree or technical certificate; 60% had a 
gross annual household income below AUD$60,000. 
Procedure 
Participants gave written informed consent. Griffith University and participating 
hospitals granted ethics approval. Partners completed the DT (National Comprehensive 
Cancer Network., Accessed February), the HADS (Zigmond AS & Snaith RP., 1983) at 
baseline, 3, 6, and 12 months post-diagnosis (Study 1) and the HADS and IES-R (Chambers 
et al., 2014; Weiss, Marmar, Wilson, & Keane, 1997) at baseline, 6, 12, 18 and 24 months 
(Study 2).  
Measures 
Distress thermometer 
The DT is widely used as an ultra-brief screening measure to assess general 
psychological distress in patients diagnosed with cancer (Mitchell, 2007; National 
Comprehensive Cancer Network., 2013). Partners reported the level of distress they were 
currently experiencing (within the past week including the day on which they were assessed) 
on a single 11-point scale, scored 0 no distress to 10 extreme distress.  
Hospital Anxiety and Depression Scale 
 The 14-item HADS (HADS-T) measured generalized anxiety (HADS-A subscale, 7 
items) and depression (HADS-D subscale, 7 items) (Zigmond & Snaith, 1983). Partners rated 
their experience of anxiety or depression symptoms in the past week on 4-point scales scored 
0 (e.g., not at all) to 3 (e.g., very often); higher scores indicate increased distress (range 0-21 
for subscales and 0-42 for total scale).  Internal consistency for HADS-A (Study 1: α = 0.85 
to 0.87; Study 2: α = 0.87 to 0.91), HADS-D (Study 1: α = 0.80 to 0.84; Study 2: α = 0.82 to 
0.86), and HADS-T (Study 1: α = 0.89 to 0.90; Study 2: α = 0.90 to 0.93) was high across all 
time points in both cohorts. In the current study, cut-off scores ≥8 on HADS-A and HADS-D 




subscales (Zigmond AS & Snaith RP., 1983) and ≥11 on HADS-T (Vodermaier & Millman, 
2011) were used to indicate participants with some level of emotional distress. 
Impact of Events Scale-Revised 
 The 22-item IES-R (Horowitz, Wilner, & Alvarez, 1979; Weiss et al., 1997) measured 
cancer-specific distress, specifically partner’s experience of intrusive or avoidant thinking 
and hyperarousal regarding the man’s PCa in the past week (Study 2 only). Items were scored 
on 5-point scales from 0 not at all to 4 extremely; higher scores indicate more cancer-specific 
distress (range 0 to 88). Internal consistency over time was excellent (α = 0.94 to 0.96). A 
cut-off score ≥33 was used in the current study to indicate high cancer-specific distress 
(Creamer, Bell, & Failla, 2003).  
Statistical analyses 
Receiver operating characteristics (ROC) analysis evaluated diagnostic accuracy of 
the DT to detect clinical cases across time against the HADS-A, HADS-D, HADS-T and IES-
R. ROC analysis generates a curve and the area under the curve (AUC), in this context, 
represents the diagnostic utility of the DT as compared to the HADS/IES-R across the full 
range of DT scores (0-10). An AUC of 1 represents perfect agreement between the DT and 
the HADS/IES-R and an AUC of 0.5 indicates that the probability of the DT detecting a 
person experiencing distress (as determined by the HADS/IES-R scales) is no greater than 
chance (Metz, 1978). For the current study, an AUC of 0.60-0.69 is considered to have poor 
discriminating ability, 0.70-0.79 is fair, 0.80-0.89 is good and 0.90 or above is excellent (Ma 
et al., 2014; Metz, 1978). Sensitivity (proportion of partners correctly identified as distressed) 
and specificity values (proportion of partners correctly identified as not distressed) were 
calculated for each of the DT scale points. The optimal DT thresholds were then selected 
according to two methods: the Youden Index (the cut-off is selected as the point on the AUC 
that is farthest from chance, corresponding to the maximum value of (sensitivity + specificity 




− 1) (Youden., 1950), and the point on the ROC closest to (0,1) indicating perfect 
classification of partners with and without clinical distress. Table 1 shows the optimal DT 
cut-offs according to the two selection methods along with the AUC, sensitivity, specificity, 





Distress thermometer scores at baseline (M = 2.79, SD = 2.66), 3 months (M = 1.87, 
SD = 2.47), 6 months (M = 1.72, SD = 2.14) and 12 months (M = 1.52, SD = 2.06) showed 
that on average, partner distress decreased after the first 6 months. The proportion of partners 
who would be considered distressed using DT cut-offs suggested for caregivers of patients 
with cancer in prior research was identified. Based on a DT cut-off ≥4 (Zwahlen et al., 2008), 
23.3% of partners were distressed at baseline, and this reduced to 14.5% and 14.2% at 3 and 
6 months (by which time most men had received treatment), respectively, and decreased 
further to 11.5% at 12 months. With a DT cut-off ≥5 (Zwahlen et al., 2008), 18.5% were 
identified as distressed at baseline and the proportion of partners who were distressed 
decreased over time (3 months 12.6%; 6 months 9.0%; 12 months 7.4%). This pattern was 
also consistent with a DT cut-off ≥6 (Hawkes et al., 2010), with 12.7% of partners identified 
as distressed at baseline with subsequent declines in these numbers (3 months 8.2%; 6 
months 5.2%; 12 months 4.1%).  
Diagnostic accuracy of the DT compared to the HADS 
Comparing the DT to HADS-T at baseline, the AUC was 0.84 (95% CI 0.78-0.90) 
with an optimal DT cut-off of ≥4 according to both classification methods (Table 1). The 
corresponding values for ROC curves for the HADS-T at 3, 6 and 12 months remained fairly 




stable, with a decrease in the threshold to ≥3 at 3 and 6 months and then to ≥2 at 12 months. 
Sensitivity of the DT compared with HADS-T across the time points was low (61% to 69%), 
however, specificity was higher (73% to 88%). A similar pattern of results to the HADS-T 
were noted for the HADS-A from baseline to 12 months, except for 2 different optimal DT 
cut-off points being identified at 3 months of ≥3 (Youden Index) and ≥2 (point on the ROC 
closest to (0,1)). Both cut-off points had low sensitivity (61.4% and 68.2%) and higher 
specificity (83.5% and 73.0%).  
A different pattern was evident for the HADS-D. At baseline, the AUC was 0.84 
(95% CI 0.71-0.96) with a DT cut-off of ≥5 maximising sensitivity (87.5%) and specificity 
(82.7%). At 3 months, the accuracy of the DT relative to the HADS-D decreased to 0.71 
(95% CI 0.54-0.88) and optimal cut-offs were determined as ≥5 (Youden Index) or ≥3 (the 
point on the ROC closest to (0,1)). Both cut-offs had very low sensitivity (50.0% and 58.3%), 
however, specificity was higher (88.4% and 73.5%). Diagnostic accuracy of the DT 
compared to the HADS-D at 3 months was similar to the 6 month and 12 month time points, 
although the optimal DT cut-offs lowered to ≥2 and ≥3, respectively.  
Study 2 
Psychological distress 
Mean scores on the DT suggest that partner distress remained relatively unchanged 
from baseline (M = 1.91, SD = 2.40), 6 months (M = 1.94, SD = 2.44), 12 months (M = 1.95, 
SD = 2.51), and 18 months (M = 1.99, SD = 2.47), with a slight decline at 24 months (M = 
1.77, SD = 2.42). Using the DT cut-offs suggested for caregivers in prior research, a cut-off 
≥4 (Zwahlen et al., 2008) identified18.0% of partners as distressed at baseline and this 
proportion remained relatively stable over time (6 months 17.5%, 12 months 17.2%, 18 
months 18.0%, 24 months 16.7%). A DT cut-off ≥5 (Zwahlen et al., 2008) classified 




approximately 10% of partners as distressed over time (baseline 9.8%, 6 months 11.7%, 12 
months 11.1%, 18 months 10.8%, 24 months 10.6%); and a DT cut-off ≥6 (Hawkes et al., 
2010) identified less than 10% of partners as distressed (baseline 6.1%, 6 months 7.3%, 12 
months 8.6%, 18 months 8.0%, 24 months 7.0%).  
 
 
Diagnostic accuracy of the DT compared to the HADS 
For the HADS-T at baseline, a cut-off score of ≥2 yielded the optimal ratio of 
sensitivity (82.7%) and specificity (75.3%) with an AUC of 0.85 (95% CI 0.81-0.89). 
Accuracy of the DT compared to the HADS-T remained high (AUCs ≥0.85) at 6, 12 and 18 
months, and decreased slightly at 24 months (AUC = 0.81, 95% CI 0.76-0.87). However, 
sensitivity reduced at 6, 12, and 18 months and specificity increased in the same time frame 
(Table 1). At the 24-month assessment, sensitivity (77.1%) and specificity (73.0%) were 
more balanced. The optimal DT cut-off was ≥3 at 6, 12, and 18 months and reduced to ≥2 at 
24 months. 
Compared to the HADS-A subscale, the DT initially showed a cut-point ≥3 at 
baseline (and again at 12 months) as providing the best balance of sensitivity (73.1%) and 
specificity (79.8%). However, the optimal DT cut-point reduced to ≥2 at 6, 18, and 24 
months (Table 1). An alternative DT cut-off ≥1 was suggested at 24 months (Youden) and 
although sensitivity was high (90.2%), specificity was poor (59.2%). All AUCs were >0.80 
supporting good accuracy overall across time for the DT compared to the anxiety subscale 
(Table 1).  
The AUC score at baseline (0.87, 95% CI 0.82-0.92) showed good accuracy for the 
DT as compared to the HADS-D subscale, with a cut-off ≥4 providing optimal balance 
between sensitivity (79.5%) and specificity (82.3%). At 6, 12, and 24 months, the DT cut-off 




providing the best balance for sensitivity and specificity reduced to ≥3 (ROC (0,1)) (Table 1). 
A cut-point ≥3 (Youden) was also identified for 18 months (AUC = 0.92, 95% CI 0.88-0.95), 
however a cut-off ≥4 (ROC (0,1)) gave a better balance between sensitivity (86.2%) and 
specificity (82.8%). For all remaining time points, the DT showed good accuracy with AUCs 
ranging from 0.81 (6 months) to 0.89 (24 months) (Table 1). 
 
Diagnostic accuracy of the DT compared to the IES-R 
 At baseline, the AUC was 0.83 (95% CI 0.75-0.91) with an optimal DT cut-off of ≥3 
(Table 1). Although accuracy of the DT across time remained high (AUCs ranged from 0.87-
0.91), the optimal DT cut-off was not consistent over time. At 6 months a DT cut-off ≥5 
provided a good balance between sensitivity (85.0%) and specificity (85.8%), and at 12 
months this reduced to ≥3 (Youden Index) or ≥4 (ROC (0,1)); increased to ≥5 (Youden 
Index) or ≥4 (ROC (0,1)) at 18 months; and remained at ≥5 at 24 months. Over time, 
depending on the optimal DT cut-off identified, sensitivity and specificity values ranged from 
71% to 95% and 71% to 87%, respectively.   
Discussion 
 In the current study, overall diagnostic accuracy of the DT in female partners of men 
with PCa was inconsistent. Although AUC scores suggested that performance of the DT 
compared to the HADS (AUC range 0.71 to 0.92) and IES-R (AUC range 0.83 to 0.94) was 
acceptable, other diagnostic indicators varied and were context-dependent. Specifically, when 
performance of the DT was compared to the HADS within and between studies, optimal DT 
cut-offs to detect partner distress ranged from ≥2 to ≥5; against the IES-R, optimal DT cut-
offs ranged from ≥3 to ≥5; with no clear pattern emerging to indicate a single optimal DT 
cut-point. Close to the time of the man’s diagnosis and treatment, the sensitivity of the DT in 
detecting partners’ distress was consistently lower than specificity, regardless of the DT cut-




off used. When men were beyond treatment and well into survivorship, sensitivity was either 
higher than specificity or each value was more equally balanced. In the context of screening 
for a common condition such as distress, high sensitivity is needed to avoid overlooking 
partners who are in fact distressed (Youngstrom, 2014). However, unless the measure has 
reasonable specificity, there is a risk of over-diagnosis of distress resulting in unnecessary 
treatment or referral and impact on already limited availability of supportive care 
professionals and resources in clinical care. Thus, use of the DT alone to detect female 
partners in need of further assessment or psychological intervention appears problematic and 
more comprehensive screening measures may be needed.   
 Ultra-short screening measures with 2 to 4 items tend to have better sensitivity than 
single item measures (Mitchell & Coyne, 2007) although, similar to the DT, specificity may 
be moderate and evaluation with a more in-depth measure required (Lazenby et al., 2015; 
Mitchell & Coyne, 2007). The four item Patient Health Questionnaire (PHQ-4) is an ultra-
short measure assessing anxiety (Generalised Anxiety Disorder [GAD]-2) and depression 
(PHQ-2) with acceptable psychometric properties that appears promising for use in primary 
care settings with patients (Kroenke, Spitzer, Williams, & Löwe, 2009) and warrants further 
investigation in cancer settings (Pirl et al., 2014). The PHQ-4 is also increasingly being 
utilised in cross-sectional or longitudinal predictive studies to measure distress as a predictor 
or outcome in partners (e.g., Ernst et al., 2017; Haun et al., 2014; Pankrath et al., 2016) and 
caregivers (e.g., Oh, 2017; Sklenarova, Krümpelmann, et al., 2015) of cancer patients. 
However, no studies have examined the diagnostic utility of the PHQ-4 compared to other 
ultra-short or more in-depth screening measures such as the HADS in partners or caregivers 
of cancer patients. This is an area worthy of further investigation.  
In some studies of patients with cancer, distress as measured by the DT has aligned 
more closely with the anxiety subscale of the HADS (Gil et al., 2005). To address this, 




researchers have proposed the use of additional emotion thermometers (e.g., mood 
thermometer) to supplement the DT and increase sensitivity to better detect multiple domains 
of distress (e.g., depression) (Gil et al., 2005; Mitchell, 2007; Vodermaier et al., 2009). For 
instance, Mitchell and colleagues (Mitchell, Baker‐Glenn, Granger, & Symonds, 2010) 
proposed the use of a 5-item emotion thermometers tool covering distress, anxiety, 
depression, anger and need for help and showed that sensitivity of the DT in detecting 
distressed patients with cancer can be improved by including these additional thermometers 
(Mitchell, Baker‐Glenn, Park, Granger, & Symonds, 2010). For partners or caregivers, there 
may also be other dimensions of distress such as caregiver burden that warrant inclusion. 
However, as is clear from the current study, suitable approaches for patients may not transfer 
directly to partners and a new approach may be needed potentially building on the work of 
Mitchell and colleagues (Mitchell, Baker‐Glenn, Granger, et al., 2010; Mitchell, Baker‐
Glenn, Park, et al., 2010) to incorporate partner- or caregiver-specific issues.  
  Overall, our results are not consistent with other validations of the DT with 
caregivers/family members in cancer (Hawkes et al., 2010; Zwahlen et al., 2008). Of note, 
these previous studies relied on single sample, cross-sectional designs within which temporal 
and contextual variations will not be elucidated. A strength of the current study is the 
inclusion of two cohorts of partners prospectively assessed at different time points in the 
cancer trajectory. A limitation of the current study is the small number of female partners 
who were identified as depressed (~8%) resulting in wide confidence intervals around the 
AUC scores and potentially increasing uncertainty regarding optimal thresholds (Chambers et 
al., 2014). As noted, there may also be other dimensions of distress that are more salient for 
partners (e.g., caregiver burden, Adelman, Tmanova, Delgado, Dion, & Lachs, 2014) but 
were not assessed in the current study. Future research could examine alternative or a broader 




range of criterion measures, including those developed specifically for partners/caregivers, 
against which to compare suitability or otherwise of the DT.      
In conclusion, when compared to well-used and validated measures of general and 
cancer-specific distress overall diagnostic performance of the DT in female partners of men 
with PCa was not strong. Optimal cut-offs and sensitivity and specificity of the DT varied 
across time and between cohorts with no clear pattern emerging. Thus, at this point in time, it 
is not possible to draw firm conclusions about optimal DT cut-offs or recommend use of the 
DT to detect distress in partners of men diagnosed with PCa. Further work is required to 
identify the most suitable screening measure for female partners/carers in need of 
psychological intervention that may then be implemented in acute, community and 
primary care settings.  
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Study 1 (N = 189)         
HADS-A 0 (baseline) 68/189 0.83 (0.77-0.89) ≥ 4 b 66.18 88.43 80.42 5.72 0.38 
 0  68/189 0.83 (0.77-0.89) ≥ 3 c 77.94 75.21 76.19 3.14 0.29 
 3 44/159 0.78 (0.70-0.86) ≥ 3 b 61.36 83.48 77.36 3.71 0.46 
 3 44/159 0.78 (0.70-0.86) ≥ 2 c 68.18 73.04 71.70 2.53 0.44 
 6 30/155 0.82 (0.73-0.91) ≥ 3 70.00 82.40 80.00 3.98 0.36 
 12 30/148 0.79 (0.70-0.88) ≥ 2 73.33 72.03 72.30 2.62 0.37 
          
HADS-D 0 (baseline) 16/189 0.84 (0.71-0.96) ≥ 5 87.50 82.66 83.07 5.05 0.15 
 3 12/159 0.71 (0.54-0.88) ≥ 5 b 50.00 88.44 85.53 4.32 0.57 
 3 12/159 0.71 (0.54-0.88) ≥ 3 c 58.33 73.47 72.33 2.20 0.57 
 6 6/155 0.73 (0.51-0.95) ≥ 2 83.33 63.09 63.87 2.26 0.26 
 12 11/148 0.76 (0.59-0.93) ≥ 3 63.64 79.56 78.38 3.11 0.46 
          
HADS-T 0 (baseline) 68/189 0.84 (0.78-0.90) ≥ 4 66.18 88.43 80.42 5.72 0.38 
 3 44/159 0.78 (0.70-0.86) ≥ 3 61.36 83.48 77.36 3.71 0.46 
 6 35/155 0.81 (0.72 -0.90) ≥ 3 68.57 84.17 80.65 4.33 0.37 
 12 36/148 0.76 (0.66 -0.86) ≥ 2 69.44 73.21 72.30 2.59 0.42 
          
Study 2 (N = 460)         
HADS-A 0 (baseline) 104/425 0.81 (0.76-0.86) ≥ 3 73.08 79.75 78.12 3.61 0.34 
 6 97/393 0.83 (0.79-0.88) ≥ 2 82.47 69.59 72.77 2.71 0.25 
 12 88/360 0.85 (0.80-0.90) ≥ 3 76.14 82.35 80.83 4.31 0.29 
 18  82/350 0.85 (0.81-0.90) ≥ 2 85.37 71.27 74.57 2.97 0.21 
 24 82/359 0.81 (0.76-0.86) ≥ 1 b 90.24 59.21 66.30 2.21 0.16 
 24 82/359 0.81 (0.76-0.86) ≥ 2 c 76.83 72.20 73.26 2.76 0.32 
          
HADS-D 0 (baseline) 39/423 0.87 (0.82-0.92) ≥ 4 79.49 82.29 82.03 4.49 0.25 
 6 42/393 0.81 (0.73-0.88) ≥ 3 83.33 75.78 76.59 3.44 0.22 











Area under ROC 


















 12 35/361 0.85 (0.79-0.91) ≥ 2 b 94.29 64.11 67.04 2.63 0.09 
 12 35/361 0.85 (0.79-0.91) ≥ 3 c 82.86 73.31 74.24 3.10 0.23 
 18 29/349 0.92 (0.88-0.95) ≥ 3 b 96.55 73.44 75.36 3.63 0.05 
 18 29/349 0.92 (0.88-0.95) ≥ 4 c 86.21 82.81 83.09 5.02 0.17 
 24 28/357 0.89 (0.82-0.95) ≥ 2 b 96.43 66.26 68.63 2.86 0.05 
 24 28/357 0.89 (0.82-0.95) ≥ 3 c 78.57 77.51 77.59 3.49 0.28 
          
HADS-T 0 (baseline)  110/422 0.85 (0.81-0.89) ≥ 2 82.73 75.32 77.25 3.35 0.23 
 6 107/391 0.85 (0.80-0.89) ≥ 3 72.90 85.21 81.84 4.93 0.32 
 12 98/360 0.85 (0.80-0.89) ≥ 3 75.51 84.35 81.94 4.83 0.29 
 18 93/349 0.88 (0.84-0.92) ≥ 3 78.49 84.38 82.81 5.02 0.25 
 24 83/357 0.81 (0.76-0.87) ≥ 2 77.11 72.99 73.95 2.86 0.31 
          
IES-R 0 (baseline) 27/418 0.83 (0.75-0.91) ≥ 3 85.19 70.59 71.53 2.90 0.21 
 6 20/387 0.91 (0.87-0.95) ≥ 5 85.00 85.83 85.79 6.00 0.17 
 12 22/361 0.91 (0.87-0.95) ≥ 3 b 95.45 71.98 73.41 3.41 0.06 
 12 22/361 0.91 (0.87-0.95) ≥ 4 c 81.82 81.42 81.44 4.40 0.22 
 18 21/345 0.87 (0.79-0.95) ≥ 5 b 71.43 86.11 85.22 5.14 0.33 
 18 21/345 0.87 (0.79-0.95) ≥ 4 c 76.19 80.86 80.58 3.98 0.29 
 24 17/356 0.94 (0.90-0.98) ≥ 5  88.24 87.02 87.08 6.80 0.14 
Note. DT = Distress Thermometer; HADS-A = Hospital Anxiety and Depression Scale-Anxiety subscale; HADS-D = Hospital Anxiety and Depression Scale-Depression subscale; HADS-T = 
Hospital Anxiety and Depression Scale-Total score; IES-R = Impact of Events Scale-Revised total score. 
a. Caseness defined as ≥ 8 on HADS-A or HADS-D subscales and ≥ 11 on the HADS-T; Caseness defined as ≥ 33 on IES-R. 
b. The optimal DT cut-off is given by the maximum value of the Youden index which measures the vertical distance from the line of equality to the ROC curve. 
c. The optimal DT cut-off is given by the point that is closest to the ROC (0, 1). 
d. Positive likelihood ratio=Sensitivity/(1–Specificity). 
e. Negative likelihood ratio=(1–Sensitivity)/Specificity 
